Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated mantle cell lymphoma
2023-509908-15-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Zanubrutinib plus rituximab with Bendamustine plus rituximab (2 arms). Primary endpoint: Progression-free survival by independent central review. Planned start Jan 2020; status: authorised.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-509908-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509908-15-00.